N-Ethylnorketamine: Difference between revisions

Content deleted Content added
mNo edit summary
 
(21 intermediate revisions by 15 users not shown)
Line 1:
{{Short description|Chemical compound}}
{{DISPLAYTITLE:''N''-Ethylnorketamine}}
{{Drugbox
| drug_name = ''N''-Ethylnorketamine
| IUPAC_name = 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one
| image = N-Ethylnorketamine_structureEthylnorketamine.pngsvg
| width = 200
 
Line 11 ⟶ 12:
| legal_CA = Schedule I
| legal_UK = Class B
| legal_DE = NpSG
 
<!--Identifiers-->
| CAS_number = 1354634-10-8
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TLL3802A3P
| ATC_prefix = none
| PubChem = 57483649
Line 20 ⟶ 24:
<!--Chemical data-->
| C=14 | H=18 | Cl=1 | N=1 | O=1
| molecular_weight = 251.751 g/mol
| smiles = Clc2ccccc2C1(NCC)CCCCC1=O
| StdInChI = 1S/C14H18ClNO/c1-2-16-14(10-6-5-9-13(14)17)11-7-3-4-8-12(11)15/h3-4,7-8,16H,2,5-6,9-10H2,1H3
Line 27 ⟶ 30:
 
'''''N''-Ethylnorketamine''' ('''ethketamine''', '''NENK''', '''2-Cl-2'-Oxo-PCE''') is a [[designer drug]] which is presumed to have similar properties to [[ketamine]], a [[Dissociative drug|dissociative]] [[anesthesia|anesthetic]] drug with [[hallucinogen]]ic and [[sedative]] effects. It has been sold over the internet since around September 2012, and identified in seized drug samples by analytical laboratories in the UK and other European countries.<ref>[http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine Report (2012)]</ref>
 
It is an [[NMDA receptor]] antagonist. In mice its antidepressant effects are dependent on activation of [[AMPA receptor|AMPA]] and [[5-HT2 receptor|5-HT2]] receptors, as blocking those abolishes said activity.<ref name="Sayson_2019">{{cite journal | vauthors = Sayson LV, Botanas CJ, Custodio RJ, Abiero A, Kim M, Lee HJ, Kim HJ, Yoo SY, Lee KW, Ryu HW, Acharya S, Kim KM, Lee YS, Cheong JH | display-authors = 6 | title = The novel methoxetamine analogs N-ethylnorketamine hydrochloride (NENK), 2-MeO-N-ethylketamine hydrochloride (2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride (4-MeO-NEK) elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors | journal = Psychopharmacology | volume = 236 | issue = 7 | pages = 2201–2210 | date = July 2019 | pmid = 30891619 | doi = 10.1007/s00213-019-05219-x | s2cid = 253743164 }}</ref>
 
==Legal Status==
 
As of October 2015 NENK is a controlled substance in the United Kingdom,<ref>[http://www.legislation.gov.uk/ukdsi/2013/9780111532980/pdfs/ukdsiem_9780111532980_en.pdf Explanatory Memorandum to the Misuse of Drugs (1971) Amendment Order 2013]</ref> China,<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinesezh | accessdateaccess-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date=1 October 2015 | url-status=dead }}</ref> and the US state of Alabama.<ref>{{cite web | url=https://legiscan.com/AL/text/SB333/2014 | title=Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd. | date=March 2014 | accessdateaccess-date=28 September 2015}}</ref>
 
==Arylcyclohexylamines==
{{Arylcyclohexylamines}}
 
==References==
{{Reflist}}
 
 
{{Depressants}}
{{Hallucinogens}}
{{Glutamate receptor modulators}}
{{Glutamatergics}}
 
{{DEFAULTSORT:Ethylnorketamine, N-}}
 
[[Category:Chloroarenes]]
==[[Category:Arylcyclohexylamines==]]
[[Category:2-Chlorophenyl compounds]]
[[Category:ChloroarenesDesigner drugs]]
[[Category:Dissociative drugs]]
[[Category:Euphoriants]]
[[Category:Designer drugs]]